Molecular diagnostics are transforming the way your lab tests
for infectious diseases and solid tumors. Increasingly, molecular
tests supplement and often replace conventional diagnostic assays.
They're also being used to obtain prognostic data, and in some
cases dictate therapy.
Molecular-based infectious disease assays enhance client/physician
satisfaction by providing diagnostic information that yield quick
results, making clinical decisions much easier. As a result, clinicians
are increasingly asking for these tests.
pathologists have been the experts on diagnostic assays, helping
physicians determine the most appropriate laboratory tests
for their patients. But with the new assays being marketed
directly to clinicians, they're ordering tests themselves,
bypassing the pathologist. As a result, pathologists are starting
to see a reduction in their position as decision-maker when
it comes to choosing the most appropriate tests.
As a pathologist, it's critical that you stay current on the latest
trends in molecular testing to preserve your role in patient management.
Do you have the most current information on infectious disease
testing? Are the new assays really faster and more accurate than
conventional ones? How will you deal with the complexities and
challenges of the new tests? And what are the benefits of these
tests to both doctors and their patients?
the answers to these questions and more when you attend the
latest Dark Report and DARKDAILY.COM audio conference "Molecular
Diagnostics for Community Hospital Labs: Hitting Clinical
and Financial Home Runs in Infectious Disease and Oncology
Testing" that was on Wednesday, August 25, 2010.
Listen as our panel provides details of the most commonly
requested tests and offers insight into how to handle clinician
requests for the new assays.
You'll get details on the latest solid tumor molecular assays
and find out what assays to expect in the future. Learn how to
compare the different types of assays and determine when it's
appropriate to advise against a test, send tissue out, or bring
a test in-house.
How do you decide which tests to perform in-house and which ones
to outsource to other labs? Does it make sense for your lab to
develop molecular diagnostics capabilities to detect infectious
agents? Treatment decisions often can't wait the 2-4 days that
reference labs need to turn these tests around. So if faster results
help you prevent more infections, doesn't it make sense to do
And of course it's not only about the clinical benefits, which
can be substantial. There are financial considerations as well.
When a reference lab test is brought in-house, the cost savings
can be significant. But there are additional expenses to consider.
Find out how the implementation of infectious disease-based molecular
diagnostics can have a positive impact on patient care and financial
growth when you register to attend this very special event.
our experts show you how to ensure that your community hospital
lab continues to be an invaluable resource that helps clinicians
choose the right tests at the right time. Whether you're a community-based
pathologist, clinical lab director or hospital administrator,
this is one session you can't afford to miss!
DARK REPORT AUDIO CONFERENCE AT A GLANCE
COST: $245 per 90 min audio
TO ORDER AUDIO:Click
here or call 1-800-560-6363 toll-free
one low price—just $245—you and your entire
team can take part in this fast-paced, insightful audio conference.
Best of all, you'll be able to connect personally with either
of the panelists when we open up the phone lines for live Q&A.
Here's just some of what you’ll learn during this in-depth
definition of a molecular assay and, in broad terms, a description
of how they're used.
The clinical value of rapid turnaround results for infectious
disease molecular assays.
The solid tumor molecular diagnostics assays that are now considered
The relationship between outreach client numbers and molecular
cost avoidance can financially justify establishing MRSA and
enterovirus molecular testing.
financial outcome of bringing molecular assays from the reference
lab to your local clinical lab.
impact of genome patents on clinical molecular testing implementation.
to evaluate send-out resources and decide when it's right to
utility of some available proprietary molecular assays.
comparison of FISH and amplification-based methods.
equipment your lab needs to do molecular diagnostic testing.
basic algorithm to help you decide when to bring a molecular
diagnostic assay in house.
to Order Digital Audio:
2. Call toll free: 800-560-6363.
audio conference registration includes:
PowerPoint presentations from our speakers
full transcript emailed to you soon after the conference
Now!Or for more
information, call us toll-free at 800-560-6363.
L. Kiechle, MD, PhD has been the Medical Director
of Clinical Pathology for the five-hospital (1792 beds)
Memorial Healthcare System, working for Pathology Consultants
of South Broward, LLP since 2006. The laboratory system
performed 7.9 million tests in 2009. From 1988 to 2005
he was chairman of the Department of Clinical Pathology
and from 1993 to 2005, the Medical Director of Beaumont
Reference Laboratory at William Beaumont Hospital. That
laboratory performed 6.5 million tests in 2004. Dr.
Kiechle initiated molecular diagnostic testing and the
annual William Beaumont Hospital DNA Symposium in 1991.
He has directed basic research in signal transduction
pathways in insulin action and apoptosis and has published
extensively on the subject. Dr. Kiechle is the author
of the best-selling laboratory management book, The
Hitchhiker's Guide to Improving Efficiency in the Clinical
Laboratory, published by AACC Press, and co-editor of
Molecular Diagnostics: Techniques and Applications for
the Clinical Laboratory, published by Academic Press.
He lectures internationally on basic research topics,
point-of-care testing, automation, laboratory design,
outreach program and molecular diagnostics.
M Murphy, PhD is the Director of Clinical Laboratory
Operations at ProPath. Her training incluath, Dr. Murphy
was the Director of the Molecular Diagnostics Lab and
an Associate Professor of Pathologydes a B.S. in Medical
Technology from the University of Virginia, and a PhD
from the University of Louisville. She completed post-graduate
training in the Mid-Atlantic Cancer Genetics Network
and the Molecular Pathology Fellowship at Johns Hopkins
University. Prior to joining ProP and Oncology at Johns
A. Hosler, MD, PhD is a practicing pathologist
at ProPath. He specializes in dermatopathology and molecular
pathology. His training includes a B.S. at Princeton
University and an MD and PhD from The University of
Texas Southwestern Medical Center. His PhD is in the
field of immunology at the School of Biomedical Sciences.
He completed his AP/CP Pathology residency training
and dermatopathology fellowship at The Johns Hopkins
Hospital. He holds the title of Clinical Assistant Professor
at The University of Texas Southwestern Medical Center
and works closely with Dr. Murphy at ProPath in the
Molecular Diagnostics Division.
Continuing Education Credit
The American Association of Clinical Chemistry (AACC) designates
this program for a maximum of 1.5 ACCENT® credit hours towards
the AACC Clinical Chemist’s Recognition Award. AACC is an
approved provider of continuing education for clinical laboratory
scientists in the states of California, Florida, Louisiana, Montana,
Nevada, North Dakota, Rhode Island, and West Virginia.